Our proprietary real-time PCR-based assays for somatic mutation detection in cancer patients combine ultra-high sensitivity with multiplexing capabilities, speed, ease-of-use and little hands-on-time. Our somatic mutation detection assays are available for analysis of both solid and liquid samples with complementary diagnostics and monitoring of mutations in key cancer genes such as BRAF, EGFR, KRAS, MYD88, NRAS and PIK3CA.
SensiScreen® FFPE assays are designed for detection of somatic mutations from genomic DNA in solid biopsies (fresh, frozen or FFPE tissue) or other samples with high amounts of DNA (load up to 50 ng). Most SensiScreen® FFPE assays are able to robustly detect 0.25-1 % mutation in a 50 ng wild type background.
SensiScreen® Liquid assays are designed for early detection and monitoring of somatic mutations in liquid biopsies using standard real-time PCR equipment. With SensiScreen® Liquid it is possible to monitor changing levels of cancer mutations and detect newly developed mutations in cell-free DNA (cfDNA) shed into the blood or other liquid samples.
PlentiPlex™ MYD88 L265P assay is intended for in vitro diagnosis of the leucine to proline mutation in codon 265 of the Myeloid differentiation primary response 88 protein (MYD88 L265P) in genomic DNA (gDNA) samples. The obtained results of the PlentiPlex™ MYD88 L265P assay are intended for assisting in the discrimination between patients with Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma.